| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
β-Amyloid 12-20 targets amyloid-beta aggregation pathways and metal binding. The peptide fragment is involved in metal binding and may play a role in the formation of amyloid plaques in the brains of Alzheimer's disease patients. The VFF triad at positions 18-20 is suggested to have amnestic effects. The peptide is used as a research tool to study the structure, function, and aggregation of amyloid-beta.
|
|---|---|
| ln Vitro |
Recommendations for Beta-Amyloid Aggregation: The protocol we suggest is as follows. Only guidelines are provided by this protocol; it should be altered to suit your unique requirements. In cold hexafluoro-2-propanol (HFIP), dissolve the solid Aβ peptide. For at least an hour, incubate the peptides at room temperature to ensure monomerization and randomization of the structure. 2. After removing HFIP by evaporation, store the resultant peptide in a film at -20 or -80°C. 3. After the membrane has been dissolved, vortex and dilute it to the proper concentration and buffer (serum- and phenol-red-free media) using anhydrous DMSO at a concentration of 5 mM. 4. After that, age the mixture for 48 hours at 4–8°C. Soluble oligomers were found in the supernatant of the samples after they were centrifuged for 10 minutes at 4–8°C at 14,000 g. For the studies, 10-200 times the supernatant was diluted. The downstream application determines which methods are used.
In vitro, β-amyloid 12-20 is used to study the properties of amyloid-beta peptides. The peptide fragment is involved in metal binding. The VFF triad at positions 18-20 is suggested to have amnestic effects. However, specific in vitro activity data, such as aggregation kinetics or cytotoxicity, have not been detailed in the available literature. The peptide is a valuable tool for Alzheimer's disease research. |
| ln Vivo |
In vivo activity of β-amyloid 12-20 has not been extensively characterized. The peptide fragment is used as a research tool in Alzheimer's disease studies. However, specific in vivo efficacy data have not been reported. The VFF triad at positions 18-20 is suggested to have amnestic effects, but further studies are needed to confirm this in vivo.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for β-amyloid 12-20 have not been extensively developed. The peptide is primarily used to study amyloid-beta structure and aggregation. Metal binding studies may be performed to assess the peptide's interaction with metal ions. However, specific assay protocols have not been published.
|
| Cell Assay |
In vitro cell-based assays for β-amyloid 12-20 typically employ neuronal cell lines or primary neurons. Cells are treated with the peptide, and neurotoxicity is assessed by measuring cell viability. The peptide's effect on aggregation and fibril formation can be studied using Thioflavin T fluorescence assays. However, specific assay protocols have not been detailed.
|
| Animal Protocol |
In vivo animal studies with β-amyloid 12-20 have not been extensively reported. The peptide is primarily used as a research tool in Alzheimer's disease studies. No specific animal studies have been described. Future studies may involve administration of the peptide in rodent models of Alzheimer's disease.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of β-amyloid 12-20 have not been characterized. As a peptide, the compound is likely to have limited oral bioavailability and may be susceptible to proteolytic degradation. However, specific PK parameters have not been determined. The compound is used in research applications only.
|
| Toxicity/Toxicokinetics |
The toxicity profile of β-amyloid 12-20 has not been extensively characterized. The peptide is a fragment of amyloid-beta, which is associated with neurotoxicity in Alzheimer's disease. However, specific toxicity data for this peptide fragment are not available. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
β-Amyloid 12-20 is a research-grade synthetic peptide fragment of amyloid-beta (residues 12-20, sequence VHHQKLVFF). It is involved in metal binding and is used in Alzheimer's disease research. The VFF triad at positions 18-20 is suggested to have amnestic effects. The compound is not an approved therapeutic drug. Molecular formula: C₅₇H₈₃N₁₅O₁₁; molecular weight: 1154.36. Sequence: VHHQKLVFF.
|
| Exact Mass |
1153.639
|
|---|---|
| CAS # |
134649-29-9
|
| PubChem CID |
25235410
|
| Appearance |
White to off-white solid powder
|
| LogP |
-0.5
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
36
|
| Heavy Atom Count |
83
|
| Complexity |
2120
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](C(C)C)N
|
| InChi Key |
YEZCRNKNZWDABB-PZBWUIGESA-N
|
| InChi Code |
InChI=1S/C57H83N15O11/c1-32(2)23-41(54(79)72-48(34(5)6)56(81)70-42(24-35-15-9-7-10-16-35)51(76)71-45(57(82)83)25-36-17-11-8-12-18-36)67-49(74)39(19-13-14-22-58)65-50(75)40(20-21-46(59)73)66-52(77)43(26-37-28-61-30-63-37)68-53(78)44(27-38-29-62-31-64-38)69-55(80)47(60)33(3)4/h7-12,15-18,28-34,39-45,47-48H,13-14,19-27,58,60H2,1-6H3,(H2,59,73)(H,61,63)(H,62,64)(H,65,75)(H,66,77)(H,67,74)(H,68,78)(H,69,80)(H,70,81)(H,71,76)(H,72,79)(H,82,83)/t39-,40-,41-,42-,43-,44-,45-,47-,48-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
